Genomics for Disease Treatment and Prevention

Psychiatric Clinics of North America

Volumn 34, Issue 1, 2011, Pages 147-166

  Bloss, Cinnamon S ^a   Jeste, Dilip V ^b   Schork, Nicholas J ^a  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetic risk assessment; Genetic testing; Genomics; Pharmacogenomics; Public health genomics

Indexed keywords

ABACAVIR; AZATHIOPRINE; CARBAMAZEPINE; CLOPIDOGREL; IRINOTECAN; MERCAPTOPURINE; WARFARIN;

AGING; ALZHEIMER DISEASE; ANXIETY DISORDER; AUTOIMMUNE DISEASE; AUTOSOMAL DOMINANT DISORDER; BIPOLAR DISORDER; BONE MARROW TOXICITY; BREAST CANCER; CHRONIC DISEASE; COLORECTAL CANCER; CROHN DISEASE; DISEASE PREDISPOSITION; DNA SEQUENCE; DRUG METABOLISM; ECONOMIC ASPECT; EPILEPSY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HERITABILITY; HUMAN; ISCHEMIC HEART DISEASE; LAW; LONGEVITY; MAJOR DEPRESSION; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MENTAL HEALTH CARE; MONITORING; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PUBLIC HEALTH; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL ASPECT; STROKE; TREATMENT RESPONSE; TRIGEMINUS NEURALGIA; VENOUS THROMBOEMBOLISM;

DRUG DISCOVERY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HEALTH POLICY; HUMANS; INDIVIDUALIZED MEDICINE; MENTAL DISORDERS; MENTAL HEALTH SERVICES; PRIMARY PREVENTION;

EID: 79951563807     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2010.11.005     Document Type: Review

References (97)

1. Ginsburg G.S., Willard H.F. Genomic and personalized medicine: foundations and applications. Transl Res 2009, 154(6):277-287.
2. Genomics frequently asked questions Available at:, Accessed July 18, 2010. http://www.ct.gov/dph/cwp/view.asp%3Fa%3D3134%26q%3D387810.
3. Nebert D.W., Zhang G., Vesell E.S. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 2008, 40(2):187-224.
4. Colby B. Outsmart your genes: online companion to the book and guide to predictive medicine Available at:, Accessed July 18, 2010. http://www.outsmartyourgenes.com/history.html.
5. Lander E.S., Schork N.J. Genetic dissection of complex traits. Science 1994, 265(5181):2037-2048.
6. Lederberg J., McCray A.T. Ome sweet 'omics-a genealogical treasury of words. The Scientist 2001, 15(7).
7. Leder P. Retrospective. Marshall Warren Nirenberg (1927-2010). Science 2010, 327(5968):972.
8. First successful laboratory production of human insulin announced 1978, Genentech, Inc, San Francisco (CA).
9. Lander E.S., Weinberg R.A. Genomics: journey to the center of biology. Science 2000, 287(5459):1777-1782.
10. Venter J.C., Adams M.D., Myers E.W., et al. The sequence of the human genome. Science 2001, 291(5507):1304-1351.
11. Lander E.S., Linton L.M., Birren B., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409(6822):860-921.
12. International HapMap Consortium The International HapMap Project. Nature 2003, 426(6968):789-796.
13. International HapMap Consortium A haplotype map of the human genome. Nature 2005, 437(7063):1299-1320.
14. Collins F.S., Guyer M.S., Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science 1997, 278(5343):1580-1581.
15. Uher R. The role of genetic variation in the causation of mental illness: an evolution-informed framework. Mol Psychiatry 2009, 14(12):1072-1082.
16. Klein R.J., Zeiss C., Chew E.Y., et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308(5720):385-389.
17. Cournil A., Kirkwood T.B. If you would live long, choose your parents well. Trends Genet 2001, 17(5):233-235.
18. Gudmundsson H., Gudbjartsson D.F., Frigge M., et al. Inheritance of human longevity in Iceland. Eur J Hum Genet 2000, 8(10):743-749.
19. McGuffin P., Rijsdijk F., Andrew M., et al. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003, 60(5):497-502.
20. Kieseppa T., Partonen T., Haukka J., et al. High concordance of bipolar I disorder in a nationwide sample of twins. Am J Psychiatry 2004, 161(10):1814-1821.
21. Feldman M.W., Lewontin R.C. The heritability hang-up. Science 1975, 190(4220):1163-1168.
22. Manolio T.A., Brooks L.D., Collins F.S. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008, 118(5):1590-1605.
23. Manolio T.A., Collins F.S. The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med 2009, 60:443-456.
24. Vineis P., Pearce N. Missing heritability in genome-wide association study research. Nat Rev Genet 2010, 11(8):589.
25. Manolio T.A., Collins F.S., Cox N.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461(7265):747-753.
26. Bloss C.S., Schiabor K.M., Schork N.J. Human behavioral informatics in genetic studies of neuropsychiatric disease: multivariate profile-based analysis. Brain Res Bull 2010, 83(3-4):177-188.
27. Halaschek-Wiener J., Amirabbasi-Beik M., Monfared N., et al. Genetic variation in healthy oldest-old. PLoS One 2009, 4(8):e6641.
28. Scott A.A., Bloss C.S., Murray S.S., et al. Large scale candidate gene resequencing in anorexia nervosa 2009, World Congress of Psychiatric Genetics, San Diego (CA).
29. Park J.H., Wacholder S., Gail M.H., et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet 2010, 42(7):570-575.
30. dbGaP: genotypes and phenotypes Available at:, Accessed August 20, 2010. http://www.ncbi.nlm.nih.gov/gap.
31. PharmGKB: pharmacogenomics knowledge base Available at:, Accessed August 20, 2010. http://www.pharmgkb.org/.
32. Elias D.J., Topol E.J. Warfarin pharmacogenomics: a big step forward for individualized medicine: enlightened dosing of warfarin. Eur J Hum Genet 2008, 16(5):532-534.
33. Carlquist J.F., Horne B.D., Muhlestein J.B., et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006, 22(3):191-197.
34. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352(22):2285-2293.
35. Lesko L.J., Zineh I. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics 2010, 11(4):507-512.
36. Ferrell P.B., McLeod H.L. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008, 9(10):1543-1546.
37. Table of valid genomic biomarkers in the context of approved drug labels Available at:, Accessed July 20, 2010. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
38. Vojvoda D., Grimmell K., Sernyak M., et al. Monozygotic twins concordant for response to clozapine. Lancet 1996, 347(8993):61.
39. Wehmeier P.M., Gebhardt S., Schmidtke J., et al. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res 2005, 133(2-3):273-276.
40. Muller D.J., Schulze T.G., Knapp M., et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001, 104(5):375-379.
41. Franchini L., Serretti A., Gasperini M., et al. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998, 32(5):255-259.
42. Clinical data achieves validation of genetic biomarker for determining risk of clozapine induced agranulocytosis Available at:, Accessed July 18, 2010. http://www.clda.com/uploads/Clozapine-April19-FINAL.pdf.
43. Arranz M.J., Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use?. Schizophr Bull 2008, 34(6):1130-1144.
44. Caspi A., Sugden K., Moffitt T.E., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301(5631):386-389.
45. Uher R. The implications of gene-environment interactions in depression: will cause inform cure?. Mol Psychiatry 2008, 13(12):1070-1078.
46. Nemeroff C.B., Heim C.M., Thase M.E., et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A 2003, 100(24):14293-14296.
47. Risch N., Herrell R., Lehner T., et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 2009, 301(23):2462-2471.
48. Bates G.P. History of genetic disease: the molecular genetics of Huntington disease-a history. Nat Rev Genet 2005, 6(10):766-773.
49. Huang E., Huang A. Breast cancer and genomic medicine. Genomic and personalized medicine 2009, 869-878. Elsevier, Durham (NC). H. Willard, G.S. Ginsburg (Eds.).
50. Memorial Sloan-Kettering Cancer Center: breast/ovarian cancer: BRCA1 & BRCA2 Available at:, Accessed July 22, 2010. http://www.mskcc.org/mskcc/html/8623.cfm%2345826.
51. Schwartz G.F., Hughes K.S., Lynch H.T., et al. Proceedings of the international consensus conference on breast cancer risk, genetics, risk management, April, 2007. Cancer 2008, 113(10):2627-2637.
52. Wray N.R., Goddard M.E., Visscher P.M. Prediction of individual genetic risk of complex disease. Curr Opin Genet Dev 2008, 18(3):257-263.
53. Purcell S.M., Wray N.R., Stone J.L., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460(7256):748-752.
54. Meigs J.B., Shrader P., Sullivan L.M., et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008, 359(21):2208-2219.
55. Sebastiani P., Solovieff N., Puca A., et al. Genetic signatures of exceptional longevity in humans. Science 2010, DOI:10.1126/science.1190532.
56. Lamond A.J., Depp C.A., Allison M., et al. Measurement and predictors of resilience among community-dwelling older women. J Psychiatr Res 2008, 43(2):148-154.
57. Pollack A. F.D.A. Faults companies on unapproved genetic tests 2010, The New York Times, New York.
58. Available at:, Accessed June 4, 2009. http://www.navigenics.com/.
59. Available at:, Accessed June 4, 2009. http://www.decodeme.com/.
60. Available at:, Accessed June 4, 2009. https://www.23andme.com/.
61. Available at:, Accessed January 13, 2010. http://www.pathway.com/.
62. Gurwitz D., Bregman-Eschet Y. Personal genomics services: whose genomes?. Eur J Hum Genet 2009, 17(7):883-889.
63. McBride C.M., Alford S.H., Reid R.J., et al. Putting science over supposition in the arena of personalized genomics. Nat Genet 2008, 40(8):939-942.
64. Ng P.C., Murray S.S., Levy S., et al. An agenda for personalized medicine. Nature 2009, 461(7265):724-726.
65. Direct-to-consumer genetic TESTS: misleading test results are further complicated by deceptive marketing and other questionable practices Available at:, Accessed July 23, 2010. http://www.gao.gov/new.items/d10847t.pdf.
66. Bloss C.S., Ornowski L., Silver E., et al. Consumer perceptions of direct-to-consumer personalized genomic risk assessments. Genet Med 2010, 12(9):556-566.
67. Bullinger L., Valk P.J. Gene expression profiling in acute myeloid leukemia. J Clin Oncol 2005, 23(26):6296-6305.
68. Dave S.S., Fu K., Wright G.W., et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006, 354(23):2431-2442.
69. Potti A., Mukherjee S., Petersen R., et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006, 355(6):570-580.
70. Potti A., Dressman H.K., Bild A., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006, 12(11):1294-1300.
71. Andersen J.N., Sathyanarayanan S., Di Bacco A., et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2010, 2(43):43ra55.
72. Starling R.C., Pham M., Valantine H., et al. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant 2006, 25(12):1389-1395.
73. Takahashi M., Hayashi H., Watanabe Y., et al. Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures. Schizophr Res 2010, 119(1-3):210-218.
74. Scherzer C.R., Eklund A.C., Morse L.J., et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 2007, 104(3):955-960.
75. Lovrecic L., Kastrin A., Kobal J., et al. Gene expression changes in blood as a putative biomarker for Huntington's disease. Mov Disord 2009, 24(15):2277-2281.
76. Fehlbaum-Beurdeley P., Jarrige-Le Prado A.C., Pallares D., et al. Toward an Alzheimer's disease diagnosis via high-resolution blood gene expression. Alzheimers Dement 2010, 6(1):25-38.
77. Oeseburg H., de Boer R.A., van Gilst W.H., et al. Telomere biology in healthy aging and disease. Pflugers Arch 2010, 459(2):259-268.
78. Davis J.C., Furstenthal L., Desai A.A., et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat Rev Drug Discov 2009, 8(4):279-286.
79. Papadopoulos N., Kinzler K.W., Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol 2006, 24(8):985-995.
80. Healy M. As genetic testing races ahead, doctors are left behind 2009, Los Angeles Times, Los Angeles (CA).
81. Toner B. Scripps spearheads new association to create online 'genomic medicine university' to educate physicians 2010, Pharmacogenomics Reporter, La Jolla (CA).
82. Ethical, legal, and social issues research Available at:, Accessed August 20, 2010. http://www.ornl.gov/sci/techresources/Human_Genome/research/elsi.shtml.
83. McBride C.M., Bowen D., Brody L.C., et al. Future health applications of genomics: priorities for communication, behavioral, and social sciences research. Am J Prev Med 2010, 38(5):556-565.
84. Stunkard A.J., Foch T.T., Hrubec Z. A twin study of human obesity. JAMA 1986, 256(1):51-54.
85. Stunkard A.J., Sorensen T.I., Hanis C., et al. An adoption study of human obesity. N Engl J Med 1986, 314(4):193-198.
86. Zdravkovic S., Wienke A., Pedersen N.L., et al. Heritability of death from coronary heart disease: a 36-year follow-up of 20 966 Swedish twins. J Intern Med 2002, 252(3):247-254.
87. The genetic basis of common diseases 2002, 457-480. Oxford University Press, New York. R. King, J. Rotter, A. Motulsky (Eds.).
88. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343(2):78-85.
89. Gatz M., Pedersen N.L., Berg S., et al. Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci 1997, 52(2):M117-M125.
90. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003, 60(12):1187-1192.
91. Sullivan P.F., Neale M.C., Kendler K.S. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000, 157(10):1552-1562.
92. McGuffin P., Katz R., Watkins S., et al. A hospital-based twin register of the heritability of DSM-IV unipolar depression. Arch Gen Psychiatry 1996, 53(2):129-136.
93. Hettema J.M., Prescott C.A., Kendler K.S. A population-based twin study of generalized anxiety disorder in men and women. J Nerv Ment Dis 2001, 189(7):413-420.
94. Hettema J.M., Neale M.C., Kendler K.S. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001, 158(10):1568-1578.
95. Genetic Information Nondiscrimination Act (GINA) of 2008 Available at:, Accessed July 20, 2010. http://www.genome.gov/24519851.
96. Personalized health care Available at:, Accessed July 20, 2010. http://www.hhs.gov/myhealthcare/.
97. S. 3822: Genomics and Personalized Medicine Act 2006 Available at:, Accessed July 18, 2010. http://www.govtrack.us/congress/bill.xpd%3Fbill%3Ds109-3822.